HISOAR(SZ:002099)2022-12-03 10:50Group 1: Company Overview and Financial Performance - Zhejiang Haixiang Pharmaceutical Co., Ltd. reported that its subsidiary, Ouhua Chemical, contributed 8.88% to the company's total revenue in 2018 and 2.44% to the net profit [4] - The company is focusing on expanding its product line along the anthraquinone industrial chain, with a new project for 15,500 tons of reactive dyes expected to start production in September 2019 [4][6] Group 2: Market and Product Insights - The company does not use or produce aniline, a key intermediate for disperse dyes, and its dye products are primarily reactive dyes for natural fabrics [2] - The domestic dye industry is experiencing price increases due to supply constraints, with the company planning to adjust its pricing based on market changes and raw material costs [2][3] - The company is a major global producer of KN-R, with a complete industrial chain that allows for self-sufficiency in intermediates [3] Group 3: Safety and Environmental Measures - Following the March 21 safety incident, the company has conducted thorough safety inspections and has not experienced any damage to its facilities [4] - The company invests heavily in safety and environmental measures, including employee training and the implementation of automated and closed-loop systems to enhance safety [5][6] Group 4: Future Growth and Challenges - The company anticipates significant growth in its clindamycin series products, driven by demand from international high-end markets [5] - The company faces challenges in the current environmental and safety landscape, but it is committed to maintaining its core competencies in these areas for sustainable development [6]